1. |
Meazza R, Gaggero A, Neglia F, et al. Expression of two interleukin15 mRNA isoforms in human tumors does not correlate with secretion: role of different signal peptides [J]. Eur J Immunol, 1997; 27(5)∶1049.
|
2. |
Carosella ED, RouasFreiss N, Paul P, et al. HLAG: a tolerance molecule from the major histocompatibility complex [J]. Immunol Today, 1999; 20(2)∶60.
|
3. |
D’Orazio TJ, Niederkorn JY. A novel role for TGFbeta and IL10 in the induction of immune privilege [J]. J Immunol, 1998; 160(5)∶2089.
|
4. |
SalazarOnfray F. Interleukin10: a cytokine used by tumors to escape immunosurveillance [J]. Med Oncol, 1999; 16(2)∶86.
|
5. |
Chouaib S, AsselinPaturel C, MamiChouaib F, et al. The hosttumor immune conflict: from immunosuppression to resistance and destruction [J]. Immunol Today, 1997; 18(10)∶493.
|
6. |
Matsni S, Ahlers JD, Vortmeyer AO, et al. A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL [J]. J Immunol, 1999; 163(1)∶184.
|
7. |
Adler AJ, Marsh DW, Yochum GS, et al. CD4+ T cell tolerance to parenchymal selfantigens requires presentation by bone marrowderived antigenpresenting cells [J]. J Exp Med, 1998; 187(10)∶1555.
|
8. |
O’Connell J, Bennett MW, O’Sullivan GC, et al. The Fas counterattack: cancer as a site of immune privilege [J]. Immunol Today, 1999; 20(1)∶46.
|
9. |
Zia A, Schildberg FM, Funke I. MHC classⅠnegative phenotype of disseminated tumor cells in bone marrow is associated with poor survival in ROMO breast cancer patients [J]. Int J Cancer, 2001; 93(4)∶566.
|
10. |
Feinmesser M, Sulkes A, Morgenstern S, et al. HLADR and beta 2 microglobulin expression in medullary and atypical medullary carcinoma of the breast: histopathologically similar but biologically distinct entities [J]. J Clin Pathol, 2000; 53(4)∶286.
|
11. |
Lefebvre S, Antoine M, Uzan S, et al. Specific activation of the nonclassical class Ⅰ histocompatibility HLAG antigen and expression of the ILT2 inhibitory receptor in human breast cancer [J]. J Pathol, 2002; 196(3)∶266.
|
12. |
Emtage PC, Wan Y, Bramson JL, et al. A double recombinant adenovirus expressing the costimulatory molecule B71 (murine) and human IL2 induces complete tumor regression in a murine breast adenocarcinoma model [J]. J Immunol, 1998; 160(5)∶2531.
|
13. |
Emtage PC, Wan Y, Muller W, et al. Enhanced interleukin2 gene transfer immunotherapy of breast cancer by coexpression of B71 and B72 [J]. J Interferon Cytokine Res, 1998; 18(11)∶927.
|
14. |
Giovarelli M, Musiani P, Garotta G, et al. A “stealth effect”: adenocarcinoma cells engineered to express TRAIL elude tumorspecific and allogeneic T cell reactions [J]. J Immunol, 1999; 163(9)∶4886.
|
15. |
Herrnring C, Reimer T, Jeschke U,et al. Expression of the apoptosisinducing ligands FasL and TRAIL in malignant and benign human breast tumors [J]. Histochem Cell Biol, 2000; 113(3)∶189.
|
16. |
O’Connell J, Bennett MW, O’Sullivan GC, et al. Expression of Fas (CD95/APO1) ligand by human breast cancers: significance for tumor immune privilege [J]. Clin Diagn Lab Immunol, 1999; 6(4)∶457.
|
17. |
Gutierrez LS, Eliza M, NivenFairchild T, et al. The Fas/Fasligand system: a mechanism for immune evasion in human breast carcinomas [J]. Breast Cancer Res Treat, 1999; 54(3)∶245.
|
18. |
Muschen M, Moers C, Warskulat U, et al. CD95 ligand expression in dedifferentiated breast cancer [J]. J Pathol, 1999; 189(3)∶378.
|
19. |
Muschen M, Moers C, Warskulat U, et al. CD95 ligand expression as a mechanism of immune escape in breast cancer [J]. Immunology, 2000; 99(1)∶69.
|
20. |
Kurt RA, Whitaker R, Baher A, et al. Spontaneous mammary carcinomas fail to induce an immune response in syngeneic FVBN202 neu transgenic mice [J]. Int J Cancer, 2000; 87(5)∶688.
|